Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,030 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High dose Placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions
Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

NCT01987492
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

NCT03710707
View directory record Official record
Conditions
Parkinson Disease
Interventions
DNL201, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-985 or matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 24, 2026, 4:27 AM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

NCT02169271
View directory record Official record
Conditions
Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Phase 4 Interventional

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

NCT00571285
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Vitamin D3, Vitamin D3 - high dose, Placebo
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

NCT03205917
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT03655691
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
Vehicle, botulinum toxin, Type A
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

NCT06106074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tolebrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Processed Orange and the Glycemic Response

NCT02112851
View directory record Official record
Conditions
Maximum Observed Plasma Glucose Concentration (Cmax)
Interventions
Orange flavored beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

NCT00567814
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Addiction
Interventions
Metyrapone, Oxazepam, Placebo
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

NCT02528214
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675
View directory record Official record
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
7 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

NCT02108262
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
CSL112, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

NCT03594227
View directory record Official record
Conditions
Alopecia
Interventions
ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
25
States / cities
Hot Springs, Arkansas • Rogers, Arkansas • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 24, 2026, 4:27 AM EDT